Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed the day trading at $40.98 up 2.40% from the previous closing price of $40.02. In other words, the price has increased by $2.40 from its previous closing price. On the day, 1.1 million shares were traded. RARE stock price reached its highest trading level at $43.74 during the session, while it also had its lowest trading level at $40.63.
Ratios:
For a better understanding of RARE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.65 and its Current Ratio is at 2.81. In the meantime, Its Debt-to-Equity ratio is 2.63 whereas as Long-Term Debt/Eq ratio is at 2.46.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on June 06, 2024, Upgraded its rating to Buy and sets its target price to $67 from $56 previously.
On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $72.Wells Fargo initiated its Overweight rating on December 08, 2023, with a $72 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 30 ’24 when KAKKIS EMIL D sold 11,727 shares for $42.23 per share. The transaction valued at 495,231 led to the insider holds 2,183,985 shares of the business.
KAKKIS EMIL D bought 11,727 shares of RARE for $495,264 on Dec 30 ’24. On Dec 10 ’24, another insider, KAKKIS EMIL D, who serves as the President & CEO of the company, sold 8,273 shares for $50.00 each. As a result, the insider received 413,650 and left with 2,195,712 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 3784269568 and an Enterprise Value of 4093433600. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.24 while its Price-to-Book (P/B) ratio in mrq is 10.90. Its current Enterprise Value per Revenue stands at 7.831 whereas that against EBITDA is -8.17.
Stock Price History:
The Beta on a monthly basis for RARE is 0.60, which has changed by -0.072752535 over the last 52 weeks, in comparison to a change of 0.22212577 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $37.02. The 50-Day Moving Average of the stock is -10.99%, while the 200-Day Moving Average is calculated to be -13.77%.
Shares Statistics:
Over the past 3-months, RARE traded about 844.41K shares per day on average, while over the past 10 days, RARE traded about 1222820 shares per day. A total of 92.24M shares are outstanding, with a floating share count of 86.37M. Insiders hold about 6.47% of the company’s shares, while institutions hold 95.28% stake in the company. Shares short for RARE as of 1735603200 were 4015892 with a Short Ratio of 4.76, compared to 1732838400 on 3379045. Therefore, it implies a Short% of Shares Outstanding of 4015892 and a Short% of Float of 4.99.
